Primary results from ENGOT-Ov41/GEICO 69-O/ANITA, a double-blind placebo-controlled phase 3 trial evaluating atezolizumab combined with platinum-based chemotherapy and maintenance niraparib for recurrent ovarian cancer with a platinum-free interval >6 months - González-Martín, A; Rubio-Pérez, MJ; Heitz, F; Christensen, RD; Colombo, N; Gorp, TV; Oaknin, A; Leary, A; Gaba, L; Lebreton, C; Gonzalez, LMD; Romeo, M; et al. (INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024)